Skeletal dysplasias, such as achondroplasia and hypochondroplasia, are genetic disorders that affect bone and cartilage growth, leading to significant physical challenges. Current treatment options are limited, and there is a need for therapies that directly address the underlying molecular mechanisms driving these conditions.

QED Therapeutics is focused on developing precision medicine therapies for FGFR-driven skeletal dysplasias. Their lead investigational drug, Infigratinib, targets the fibroblast growth factor receptor (FGFR) pathway, which plays a crucial role in bone development. By selectively inhibiting FGFR, Infigratinib aims to modulate skeletal growth and improve outcomes for individuals with achondroplasia and hypochondroplasia. The company's research and development efforts are centered on providing effective treatment options that address the root causes of these disorders.

Infigratinib: a selective FGFR inhibitor specifically designed for skeletal dysplasias

Clinical trials focused on achondroplasia and hypochondroplasia

FDA breakthrough therapy designation for Infigratinib in achondroplasia

Observational studies to further understand the natural history of hypochondroplasia

The primary target audience includes individuals diagnosed with FGFR-driven skeletal dysplasias, such as achondroplasia and hypochondroplasia, and the healthcare professionals who treat them.